Generic Names — lovastatin , simvastatin , pravastatin , fluvastatin , atorvastatin , cerivastatin, rosuvastatin
Common Brand Names — Mevacor, Zocor, Pravachol, Lescol, Lipitor, Baycol, Crestor
General Categories — HMG-CoA reductase inhibitor (systemic), antihyperlipidemic
Statins help reduce the risk of a heart attack in people who have:
Statins also may reduce the incidence of heart attack, stroke , and death in people who do not have cardiovascular disease.
Numerous studies suggest that statins can dramatically reduce LDL cholesterol ('bad cholesterol") levels and reduce the risk of death from heart disease. According to the US Food and Drug Administration (FDA), statins can lower LDL cholesterol levels by as much as 60%, depending on the drug and dosage. One study published in Circulation found that, with every 10 percentage points cholesterol was reduced, the risk of death from coronary heart disease dropped by 15%. Another study showed that lowering the LDL cholesterol level to <77 mg/dL (2.0 mmol/L) decreased the number of cardiovascular events, such as heart attacks or stroke among patients in the study.
The National Cholesterol Eudcation Program Adult Treatment Panel III (NCEP ATP III) guidelines of 2004 set slightly different criteria for LDL cholesterol when compared to the 2001 criteria:
Risk | 2001 | 2004 |
High | <100 mg/dL (<2.6 mmol/L) | <70 mg/dL (<1.8 mmol/L) |
Moderate | <130 mg/dL (<3.4 mmol/L) | <100 mg/dL (<2.6 mmol/L) |
Low | <160 mg/dL (<4.1 mmol/L) | <160 mg/dL (<4.1 mmol/L) |
HMG-CoA reductase is an enzyme that helps your body make cholesterol. Statins help to block this enzyme, which in turn causes your body to make less cholesterol. When you make less cholesterol, your liver makes more LDL receptors, which attract LDL particles in the blood. This reduces the amount of LDL ("bad") cholesterol in your bloodstream. Lower LDL cholesterol levels also tend to lead to lower levels of triglycerides and higher HDL (“good”) cholesterol levels in the blood. Statins have anti-inflammatory effects on blood vessels which help reduce the formation of fatty plaque on blood vessel walls.
Do not take the following with statins except on medical advice:
The following should be considered if you are taking statins:
Breastfeeding —statins may cause unwanted effects in nursing babies and therefore are not recommended for use during breastfeeding.
Children —some statins have been used effectively in a small number of children but their long-term safety in children has not been established
Pregnancy —statins may cause birth defects or other problems in the baby and therefore should not be taken during pregnancy
Take only the amount of statin ordered by your doctor .
RESOURCES:
American Heart Association
http://www.americanheart.org/
US Food and Drug Administration
http://www.fda.gov/
References:
Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med . 2006;355:549-59.
Grundy SM, Cleeman JL, Merz CN et al. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Eudcation Program Adult Treatment Panel III (NCEP ATP III) guidelines. Circulation . 2004;110:227-239.
HMG-CoA reductase inhibitors (systemic). US Pharmacopeia (USP-DI). Available at: http://www.usp.org . Accessed on January 28, 2003.
Keeping cholesterol under control. US Food and Drug Administration website. Available at:
http://www.fda.gov/fdac/features/1999/199_chol.html
. Accessed on January 28, 2003.
Lemaitre RN, Psaty B, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults. Arch Intern Med . 2002;162:1395-1400.
Middleton A, Binbrek AS, Fonseca FA, et al. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin . 2006;22: 1181-91.
Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin, and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005;7:430-8.
Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fuorodeoxyglucose positron emission tomography. J Am Coll Cardiol . 2006;48:1825-31.
Texas Heart Institute. Available at: http://www.tmc.edu/thi/ . Accessed on January 28, 2003.
*¹1/30/2009 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed/what.php : Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769-1781.
Last reviewed January 2009 by Igor Puzanov, MD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2007 EBSCO Publishing All rights reserved.